Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Vikram Sheel Kumar
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
cellular biology
therapeutics development cell death pathways |
| gptkbp:foundedYear |
2019
|
| gptkbp:founder |
Vikram Sheel Kumar
|
| https://www.w3.org/2000/01/rdf-schema#label |
Inzen Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Atlas_Venture
|
| gptkbp:location |
gptkb:Cambridge,_Massachusetts
|
| gptkbp:platform |
Thanokine Biology
|
| gptkbp:researchArea |
cellular signaling
cellular response to injury |
| gptkbp:website |
https://www.inzentherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Milton_H._Werner
|
| gptkbp:bfsLayer |
8
|